Exploring molecular phenotypes of incident breast cancer through population-based proteogenomics
Proteins play key roles in malignant transformation and represent an important hub for oncogenic signaling. Elevated levels of circulating proteins could potentially be identified years before the onset of cancer and its detection by current diagnostics. This webinar focuses on exploring the power of proteomic discoveries, at the population scale in a breast cancer cohort, and the integration of proteogenomics to generate key biological insights into risk prediction that may lead to translational applications for breast cancer prevention.
Speaker: Dr. Anders Mälarstig (Director of Target Sciences, Pfizer Worldwide Research and Development)
Olink Webinar library
Get access to this webinar, as well as the rest of our categorized library of more than 20 high-quality scientific webinars featuring presentations by leading researchers in their respective fields.
The importance of integrating multi-omics at a systemic level to generate key biological insights for cancer prevention, diagnosis, and treatment
Emerging large-scale cancer proteomics analyses at the population level
Using high-throughput proteomics to find actionable biomarkers to better understand and treat human cancer.
Original Broadcast date: November 23 2021
Dr. Mälarstig received his Ph.D. in cardiovascular genetics from Uppsala University in 2006 and then did postdoctoral training at the Karolinska Institute in Stockholm. In 2009 he joined Pfizer, where he is now director of Target Sciences. In his current role, he is responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public-private partnerships such as the SCALLOP consortium, which recently published their first article in Nature Metabolism, entitled “Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.”